A Monte- Carlo simulation of received doses by prostate and some critical organs following prostate brachytherapy using 3 isotope seeds 131Cs ,103Pd and 125 I

Authors

10.22052/1.1.15

Abstract

  Using the Monte Carlo N-Particle computer code (MCNP), doses were calculated for organs of interest such as the stomach, prostate, liver, and kidneys while patients were undergoing prostate brachytherapy. This research is important because the doses delivered to the prostate are extremely high and the organs near the prostate are potentially at risk of receiving high doses of radiation, leading to increased probabilities of adverse health effects such as cancer. In this research, MCNP version C codes were used to calculate the imparted energies to the organs of interest due to125I, 103Pdand 131Cs treatment sources.  The nearest organs to the prostate received highest energy depositions and the organs farthest from the prostate received the lowest energy depositions. Once the dose per transformation for each organ of interest is determined, then using the total transformation due to given activities of the sources over an infinite time would result in the total deposition of energy per kilogram of the related organ. All received doses in prostate were found to be 80, 96 and 102 Gy for 131Cs ، 103Pd and125I respectively. The stomach received the highest dose (2 Gy) and the lowest absorption obtained in lung (0.27 × 10-4Gy).

Keywords

References

[1] Briesmeister JF ,MCNP- A General Monte Carlo N-Particle transport code. Los Alamos national laboratory, version 4B, 1997, LA-126265. [2] M.Yazdani and A.A. Mowlavi, Determining TG-43 brachytherapy dosimetry parameters and dose distribution for a source model CS-1. Department of Physics, Tarbiat Moallem University of Sabzevar, Sabzevar, Iran. Iran. J. Radiat. Res., 2007, pp. 85-90. [3] MCNP modeling of prostate brachytherapy and organ dosimetry. Submitted to the Office of Graduate Studies of Texas A & M University. [4] Dan Theodorescu, MD, PhD, Paul Mellon Professor of Urologic Oncology, Prostate Cancer- Brachytherapy (Radioactive Seed Implantation Therapy), Department of Urology, University of Virginia Health Sciences Center. [5] R.Yaparpalvi, J.Rossinow, W.A.Cavanagh, W.Choi, L.Minsky, N.Kahan, W.Bodner, M.Garg, S.Kalnicki, C.Guha. Montefiore Medical Center and the Albert Eintein Collage of Medicine, Brox, New York and The Haakon Ragde Foundation for Advanced Cancer Studies, Seattle,WA. Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy.

Files

Share

How to cite

Statistics